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Abstract
We conducted a prospective open-label study with 100 outpatients who had sought 
psychiatric consult in private clinical practice for anxiety/sleep in subthreshold/
full blown DSM-IV Anxiety Spectrum Disorders. Clinicians, prescribed for 4 weeks 
a dietary supplement based on a formulation containing α-casozepine peptide 
300 mg/day. The comparison of all rating scales mean scores reported at T0 
versus T1 showed a statistically significant decrease (p<0.001). In Clinical Global 
Impression scale, the 54% of the sample was found to be much improved, 27% 
minimally improved and 19% showed no change. The 64% of the sample reported 
an anxiolytic effect, and among the 64 patients with sleep disorders, the 51.5% 
reported a pro-hypnotic effect. Considering patients in monotherapy with the 
dietary supplement, an anxiolytic effect was observed in 69.7% while a pro-
hypnotic effect was observed in the 62.5% of the sample. No side-effects were 
reported during the treatment with no drop-out. 
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Introduction
Anxiety Spectrum Disorders are amongst the most prevalent 
mental disorders and are responsible for reduced quality 
of life and significant disability in affected patients [1]. 
Effective treatment strategies for these conditions include 
psychotropic compounds (benzodiazepines and pro-serotonergic 
antidepressants) and psychotherapeutic interventions [2,3]. 
However, many patients do not have access to or refuse this kind 
of treatments for different reasons, including pharmacophobia, 
fear of dependence, economic and other motivations [4-6]. 
Therefore, novel nutraceutical compounds with potential 
anxiolytic effects have attracted the interest of researchers over 
the last years [7,8].
For generations, mothers have given their children a warm glass 
of milk before going to bed as a way to help them fall asleep. As 
far back as 1934, this home remedy gained scientific validation 
when it was observed that people who had taken milk and 
cornflakes were more likely to enjoy a full night of uninterrupted 
sleep [9]. Subsequently, Brezinova and Oswald showed, using 
electroencephalography, that sleep was significantly improved 
(longer and un-interrupted night sleep-time) in older people, 
when they had taken a combination of cow milk and cereals 
before going to bed [10]. In 1997, amongst pediatric researchers, 
Blass provided further evidence in the field by demonstrating 
that newborns given an infant formula containing milk fell asleep 
not solely due to nursing and being held, but specifically to 
something in milk itself [11]. Just at the beginning of the new 
millennium, it has been identified what that “something” was. 
It turned out that nutrients found in cow milk called bioactive 
peptides, chains of amino acids, exert a sedative effect on the 
brain and induce sustained sleep patterns [12]. These bioactive 
milk peptides have been shown to act on the brain GABA-A 
receptors, which represent the target of one of the most effective 
classes of sedatives: the benzodiazepines. Specifically, only one 
peptide named α-casozepine, corresponding to the 91–100 
fragment from bovine αs1-casein, expressed affinity for GABA 
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A receptor [13]. In pre-clinical models, milk peptides markedly 
reduced anxiety and improved sleep in animals subjected to 
chronic stress [14]. Authors demonstrated that the injection 
of 3 mg/kg of α-casozepine significantly reduced the epileptic 
symptoms caused by pentylenetetrazole in rats [15]. An anxiety 
reduction was also observed when the hydrolysate was tested 
in the elevated plus-maze and in the conditioned defensive 
burying rat models. Using selective antagonists of 5-HT1A, D1 
and GABA-A receptors, other authors [16] have demonstrated 
to inhibit α-casozepine anxiolytic effect, suggesting a synergic 
role of these receptors in the anxiolytic activity observed in 
mice. The α-casozepine amino acid sequence could be related 
to the carboxyterminal sequence of the polypeptide diazepam 
binding inhibitor, an endogenous ligand of the central GABA-A 
and peripheral-type benzodiazepine receptor, but α-casozepine 
activity was observed only in central GABA-A receptors [13]. More 
recently, in a double-blind placebo-controlled trial, α-casozepine 
showed improvements of stress-related symptoms in a total 
of 63 female volunteers suffering from at least one potentially 
stress-related disorder, such as anxiety, sleep problems and 
general fatigue [17]. After one month, the α-casozepine group 
significantly reduced their symptoms more than placebo, 
particularly in digestion, intellectual, cardiovascular, emotional 
and social problems. As widely known, also sleep disturbances 
benefit from psychotropic compounds with GABAergic activity. 
In this perspective, a representative sample of day-time workers 
from the general population of Japan, reporting insomnia during 
the preceding six months, was treated with α-casozepine in an 
observational study [18]. Results showed that α-casozepine 
improved sleep quality after two weeks of treatment and 
decreased the sleep latency and the daytime dysfunction after 
four weeks of treatment.
With the aim to investigate the anxiolytic and pro-hypnotic 
effect of α-casozepine, we conducted the present open-label 
prospective short-term study with 100 outpatients affected by 
Anxiety Spectrum Disorders and treated with α-casozepine for 
4 weeks.
Material and Methods
We enrolled 100 outpatients who had sought psychiatric consult 
in private clinical practice for anxiety symptoms. All patients were 
screened using the Structured Clinical Interview (SCID-I) [19] to 
assess the psychiatric diagnosis at recruitment time, considering 
spectrum condition as a clinical picture which does not necessarily 
meet all the criteria requested for the diagnosis according to the 
DSM-IV-TR (APA, 2000) [20]. However, in terms of psychometric 
assessment, inclusion criteria required a minimum score of 8 
at the Hamilton Anxiety Scale [21] and/or of 7 at the Insomnia 
Severity Index [22]. We considered only patients affected by 
Anxiety and Mood Spectrum Disorders with subthreshold or full-
blown diagnoses in relation to reported anxiety symptoms. Three 
clinicians, according to patients’ needs, proposed and prescribed 
a Dietary Supplement (DS) based on a formulation containing 
α-casozepine peptide at a dosage of 300mg/die (provided 
by Junia Pharma SRL, Italy). A written informed consent for 
participation into the study was provided by all patients, and 
the study protocol was approved by the Ethics Committee of the 
University of Pisa. With the aim to provide an evaluation over the 
course of anxious symptoms, we administered to all patients at 
recruitment time (T0) and after 4 weeks (T1) of treatment with 
DS the following rating scales: 1) the Hamilton Anxiety Scale 
(HAM-A), quantifying the severity of anxiety symptoms through 
the investigation of 14 specific items of the anxiety spectrum; 2) 
the Insomnia Severity Index (ISI), a rating scale for sleep disorders 
divided into seven multiple-choice questions on sleep quality and 
its influences in daily life; 3) the Clinical Global Impression scale 
(CGI)  [23] indicating the overall clinical evaluation by a clinician 
in terms of severity and improvement, respectively, of the 
clinical picture as a whole. Finally, 4) the therapeutic evaluation 
was assessed using the Dosage Record and Treatment Emergent 
Symptom Scale (DOTES) [24], recording concomitant treatments 
and the presence of side effects due to the ongoing treatment. 
Statistical analysis was performed using SPSS version 21 
(USA). Qualitative and quantitative analysis of response were 
conducted. Considering a clinical response to treatment of 
anxious symptoms a decrease by half of the HAM-A and/or ISI 
score at T1 and patients who reported marked improvement to 
CGI. Response rate was compared according to the diagnosis 
and in patients who took DS in monotherapy versus add on 
treatment.  Parametric variables were described as mean and 
standard deviation (SD) and were compared by paired t-test or 
independent t-test. Categorical variables were compared by χ2 
test. Statistical significance was assigned for p<0.05.
Results
Of the 100 outpatients reporting anxiety symptoms (70 females, 
mean age 39 + 14.7), 53% met a diagnosis of subthreshold 
Anxious Spectrum Disorder (patients with anxious symptoms not 
meeting all the criteria necessary for diagnosis of Anxiety and/
or Mood Disorders, according to DSM-IV-TR), 20% had Sleep 
Disorders, 16% Panic Disorder and 11% were affected by Bipolar 
Disorders (Table 1). 
After 4 weeks of treatment, it emerged that 54% of our sample 
showed a marked improvement at the CGI scale and 27% was 
found to be minimally improved, while 19% had no change. The 
comparison of CGI score (T1 versus T0) documented a statistically 
Variables  Overall Sample (n=100 ) %
 Mean age 39 years (18-78) ds=1.47
Gender Females 70%
Occupation
Employed 60%
Student 20%
Unemployed 7%
Retired 13%
Diagnosis
Anxiety Spectrum Disorders 53%
Sleep Disorder 20%
Panic Disorder 16%
Bipolar Disorder 11%
Treatment
Lactium monotherapy 43%
Lactium as add-on treatment 57%
Table 1 Demographic and clinical features of the study samples.
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significant reduction of the mean scores (3.31 ± 0.80 vs 2.54 ± 
0.95, p<0.0001). Moreover, we observed a significant reduction 
of the HAM-A mean scores comparing T1 vs T0 (12.96 ± 6.79 vs 
7.21 ± 6.19, p<0.0001).  Of the 64 patients with insomnia, the ISI 
mean score showed a significant decrease from T0 to T1 (8.45 ± 
6.48 vs. 4.9h ± 5.19, p<0.0001) (Table 2 and Figure 1). 
Considering a clinical response to treatment of anxious symptoms 
a decrease by half of the HAM-A and/or ISI score at T1, we 
documented a clinical response in the 64% of our sample. When 
comparing patients taking DS monotherapy (n=43) versus add-on 
treatment (n=57) (predominantly SSRI or SNRI antidepressants 
and mood stabilizers), we observed a clinical response in 69.7% 
of those in monotherapy (HAM-A score) at T1 versus 59.6% 
who took DS in add-on to other treatments without statistically 
significant differences. 
With regards to the 64 patients with sleep disorders, the 51.5% 
had a response in terms of ISI score at T1. Patient with sleep 
disorders and DS in monotherapy represented the 24% of the 
sample and 62.5% of them showed a clinical response in terms 
of ISI reduction at T1 while only the 45% of patients who took DS 
with other treatments, showed a clinical response (p>0.05).
According to the diagnosis, the presence of Panic Disorder was 
found to be associated with a higher (though not statistically 
significant) response to treatment than Bipolar Disorder and 
Anxious Spectrum Disorders respectively (75% vs 72% vs 53%). 
The analysis of the Dotes scores revealed that DS was not 
associated with any side effects. 
Discussion
In our sample of 100 patients with Anxiety Spectrum Disorders 
treated with a dietary supplement based on a formulation 
containing α-casozepine peptide 300 mg/day for 4 weeks, 64% 
reported an anxiolytic effect, and of the 64 patients with sleep 
disorders 51,5% reported a pro-hypnotic effect. Considering 
patients in monotherapy with DS, an anxiolytic effect was 
observed in 69,7% and 62,5% showed pro-hypnotic effect. The 
comparison of all rating scales mean scores, at T1 versus T0, 
showed a statistically significant decrease. Of note, no side-effect 
was detected in relation to DS treatment. From the analysis of 
these open-label data, it emerged that DS may be helpful to 
treat mild/moderate anxiety symptoms. Present findings seem 
consistent with the results of a recent study reporting sedative 
and anxiolytic-like effects in pentobarbital-induced sleeping 
behavior of mice, after the administration of milk collected at 
night [25]. 
Serotoninergic antidepressants and benzodiazepines are the 
most prescribed pharmacological treatment in anxiety disorders 
[26-28]. Even though in appearance they have two distinct 
mechanisms of action, serotoninergic antidepressants inhibit 
glutamatergic neurons of the amygdala through increased 
extracellular serotonin levels [29]. This inhibition engenders 
anti-anxiety action. Benzodiazepines also inhibit the amygdala 
facilitating GABAergic activity, thereby reducing fear and anxiety. 
The inhibitory action on the amygdala might be, therefore, a 
common mechanism of anti-anxiety treatments [29]. However, 
both treatments induce different side effects, serotonergic 
antidepressants being often responsible for sexual dysfunctions, 
nausea and weight gain [30], whereas benzodiazepines for 
tolerance/dependence, somnolence and cognitive deficits 
[31]. With the aim to assess the evidence about the efficacy 
of antidepressants and benzodiazepines in adults with Panic 
Disorder, a recent review analyzed 35 double-blind randomized 
controlled trials, including 6785 participants overall [32]. Authors 
found low-quality evidence suggesting no difference between 
antidepressants and benzodiazepines in terms of response 
rate. In addition, very low-quality evidence suggested a benefit 
for benzodiazepines compared to antidepressants in terms of 
dropouts due to any cause, even if confidence interval ranges 
from almost no difference to benefit with benzodiazepines. 
From this perspective, it clearly emerges the need to develop 
additional treatments with proven efficacy and tolerability in 
anxiety disorders like Panic Disorder. Even psychotherapeutic 
interventions are not always easily accessible for patients with 
anxiety disorders for economic motivations or in light of lack of 
trust in the therapist or to the effectiveness of treatment [33]. 
Nutraceutical compounds represent a novel area in a new 
era of therapeutics for Anxiety and Mood Disorders, in which 
natural compounds, generally safe and well tolerated, may 
become a valid treatment option in monotherapy or in add-on 
to benzodiazepines/antidepressants [34].  Patients frightened 
by psychopharmacological treatments, patients reporting 
side-effects beyond minimal dosages, subjects with poor 
adherence or with unsatisfactory response to treatment can 
benefit from natural compounds. In particular, those which 
contains α-casozepine might be used in the acute treatment 
phase of Anxiety Disorders in add-on to antidepressants and/
HAM-A 12.96 ds=6.79 7.21 ds=6.19 13.8 <0.0001
ISI 8.45 ds=6.48 4.91 ds=5.19 9.44 <0.0001
CGI 3.31 ds=0.80 2.54 ds=0.95 10.86 <0.0001
Table 2 Rating scales mean score course at T0 and T1.
Rating scales mean score course at T0 and T1.Figure 1
2017
Vol. 2 No. 2:  7Journal of Nutraceuticals and Food Science
4 This article is available in: http://nutraceuticals.imedpub.com/archive.php
or benzodiazepines as well as in monotherapy in prodromal or 
in maintenance phases and to treat residual symptoms. The 
potential advantages, which need to be assessed under controlled 
conditions, may be represented by a greater containment of side 
effects for lower dosages and therefore a greater adherence to 
ongoing treatment, from a reduction of the duration of overall 
treatment and a greater ease to their suspension. In addition, 
the possibility of being able to prescribe DS to special populations 
like elderly, child/adolescents, pregnant women and patient with 
conditions of poor health might be worthy of specific evaluation. 
Furthermore, from this study it emerged a double effect, anxiolytic 
and pro-hypnotic, attributed to DS that misses to antidepressants 
and that benzodiazepines tend to lose overtime.  A dietary 
supplement based on a formulation containing α-casozepine 
could be a valid option in the treatment of anxiety spectrum 
disorders in monotherapy or in add-on to serotoninergic 
antidepressants and/or benzodiazepines. 
In the interpretation of the presented results, the following 
methodological limitations need to be taken into account. The 
study was not conceived as a controlled randomized study 
and it was specifically focused on the short-term treatment. In 
addition, the studied population was not homogenous in terms 
of diagnosis, severity, comorbidities and concomitant treatment, 
being composed by diagnostic subgroups that in some cases were 
too small in order to detect a statistically significant difference. 
Nonetheless, we believe that the present uncontrolled report 
may pave the way for future controlled investigation of the 
anxiolytic and pro-hypnotic effects of DS in patients with Anxiety 
Disorders.
Conclusion
The present open-label study found a significant short-term 
anxiolytic and pro-hypnotic effect of DS in patients with Anxiety 
Spectrum Disorders, and in subjects with Panic Disorder and 
Sleep Disorders. The absence of side effects of this natural 
compound can improve the compliance to treatment, and might 
be worthy of investigation amongst special populations like 
elderly, child-adolescents and pregnant women. Future double-
blind, randomized controlled studies are needed to evaluate 
the efficacy and safety of DS treatment in the long-term and in 
different populations.
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